An Outcome Analysis of Primary Membranous Nephropathy
ConditionMembranous Nephropathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMario Negri Institute for Pharmacological Research
About this trial
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice.
The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.
Eligibility criteria
Qualifiers
Adults (≥18 years old) on the day of signing informed consent.
Diagnosis of primary membranous nephropathy
Nephrotic syndrome (proteinuria >3.5 g/24 hours)
Written informed consent to the use of recorded data for research purposes.
Disqualifiers
Legal incapacity or limited legal capacity.
Any contraindication to treatment with rituximab or other monoclonal antibody
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
2ASST HPG23 - Unità di Nefrologia24127, BergamoBG, Italy
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"24020, RanicaBG, Italy
Sponsors and collaborators
Mario Negri Institute for Pharmacological Research
Lead sponsor
Source ClinicalTrials.gov